Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2024: Fourth Quarter Results Reported net sales increased 10.7% to $6.4 billionOrganic net sales increased 10.2%Reported operating income margin of 9.0%Adjusted operating income margin(1) increased 200 bps to 29.2%Reported EPS decreased 52.7% to $1.41Adjusted EPS(1) increased 15.9% to $4.01 Fourth Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Cons ...

Core Insights - Stryker has entered into a definitive agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC, forming a new entity called VB Spine, LLC [1][2] - The transaction aims to enhance the focus and growth potential of the spinal implants business as an independent company [2][3] - VB Spine will have exclusive access to Stryker's Mako Spine and Copilot technologies for its spinal procedures, fostering a strategic partnership [2][3] Company Overview - Stryker is a global leader in medical technologies, impacting over 150 million patients annually with innovative products and services in MedSurg, Neurotechnology, and Orthopaedics [5] - Viscogliosi Brothers is a family-owned investment firm focused on the neuro-musculoskeletal industry, having founded and grown 42 businesses across more than 80 countries since its establishment in 1999 [6] - Barings, LLC is a financial partner in this transaction, managing over $421 billion in assets as of December 31, 2024 [7] Transaction Details - The sale includes a binding offer to acquire Stryker's spinal implants business in France, pending employee consultations and regulatory requirements [3] - The transaction is expected to close in the first half of 2025, with both Stryker and VB Spine continuing to operate separately until then [3]

Stryker Corporation (SYK) is scheduled to release fourth-quarter 2024 results on Jan. 28, after market close. In the last reported quarter, the company delivered an earnings surprise of 3.24%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q4 EstimatesThe Zacks Consensus Estimate for earnings is pegged at $3.87 per share, indicating an increase of 11.9% year over year.The consensus mark for revenues is pinned at $6.35 billion, implying growth of 9.2% from the prior-year reported fig ...

Stryker Corporation (NYSE: SYK ) is a fantastic company with a long history of successfully commercializing innovative products in the medical device industry. Across its diversified business, it has shown steady growth in revenues, earnings, and FCF over multiple decades. ThisI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good times and ...

Analysts on Wall Street project that Stryker (SYK) will announce quarterly earnings of $3.87 per share in its forthcoming report, representing an increase of 11.9% year over year. Revenues are projected to reach $6.35 billion, increasing 9.2% from the same quarter last year.The current level reflects a downward revision of 0.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections ove ...

Stryker Corporation (SYK) recently inked a definitive agreement to acquire all the issued and outstanding shares of common stock of Inari Medical, Inc. (NARI) for $80 per share in cash, representing a total fully diluted equity value of approximately $4.9 billion.Through the acquisition of Inari Medical, Stryker is likely to expand its portfolio and provide life-saving solutions to patients with peripheral vascular diseases.Likely Trend of SYK Stock Following the NewsFollowing the announcement, shares of th ...

Key TakeawaysShares of Inari Medical surged Monday afternoon and again Tuesday morning as reports of an imminent acquisition by Stryker turned into reality.Stryker will acquire Inari in an all-cash deal for $80 per share, valuing it at roughly $4.9 billion.The deal for the vascular medical device maker was first reported by Reuters Monday afternoon, sending Inari shares up 30% by the end of Monday trading. Inari Medical (NARI) stock skyrocketed Monday afternoon and again Tuesday morning after a report that ...

Portage, Michigan and Irvine, California, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire all of the issued and outstanding shares of common stock of Inari Medical, Inc. (NASDAQ: NARI) for $80 per share in cash, representing a total fully diluted equity value of approximately $4.9 billion. Inari, which was founded in 2011, will bring a leading peripheral vascular position in the fast-growing segment of venous ...

Portage, Michigan, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its fourth quarter and full year 2024 on Tuesday, January 28, 2025. A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company’s fourth quarter and full year that ended December 31, 2024. Stryker will host a webcast at 4:30 p.m. ET on Tuesday, January 28, 2 ...

Stryker (SYK) is well-poised for growth, backed by a robust robotic arm-assisted surgery platform, Mako, and a diversified product portfolio. An improvement in price also buoys optimism.Shares of this Zacks Rank #3 (Hold) company have risen 24.5% year to date compared with the industry’s 11.5% growth. The S&P 500 Index has increased 27.8% in the same time frame.Stryker, with a market capitalization of $142.8 billion, is one of the world’s largest medical device companies operating in the orthopedic market. ...